Sarizotan HCl - CAS 195068-07-6
Catalog number: 195068-07-6
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
Molecular Weight:
5-HT Receptor | Dopamine Receptor
Sarizotan, also known as EMD-128130, is a full 5-HT1a agonist and a dopamine D2-like agonist/partial agonist used in clinical trials for the treatment of l-dopa-induced dyskinesia.
Related CAS:
177976-12-4 (Sarizotan 2 HCl salt); 195068-07-6 (Sarizotan HCl salt); 351862-32-3 (Sarizotan free base)
Solid powder
1-[(2R)-3,4-dihydro-2H-chromen-2-yl]-N-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]methanamine;hydrochloride; EMD128130; sarizotan; 177976-12-4 (Sarizotan 2 HCl salt); 351862-32-3 (Sarizotan free base); sarizotan hydrochloride
Canonical SMILES:
1.Gateways to clinical trials.
Bayes M;Rabasseda X;Prous JR Methods Find Exp Clin Pharmacol. 2006 Jul-Aug;28(6):379-412.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, This issue focuses on the following selection of drugs:(R)-Flurbiprofen, 90Yttrium-DOTA-huJ591; ABT-510, ACP-103, Ad5-FGF4, adalimumab, ademetionine, AG-7352, alemtuzumab, Amb a 1 ISS-DNA, anakinra, apaziquone, aprepitant, aripiprazole, atazanavir sulfate; BAL-8557, bevacizumab, BMS-188797, bortezomib, bosentan, brivudine; Calcipotriol/betamethasone dipropionate, cannabidiol, caspofungin acetate, catumaxomab, CERE-120, cetuximab, ciclesonide, cilomilast, cizolirtine citrate, Cypher, cystemustine; Dalbavancin, darifenacin hydrobromide, dasatinib, deferasirox, denosumab, desmoteplase, dihydrexidine, dimethyl fumarate, dutasteride, DW-166HC; Eculizumab, enfuvirtide, entecavir, epratuzumab, erlotinib hydrochloride, escitalopram oxalate, eszopiclone, etoricoxib, everolimus; Fallypride, febuxostat, fenretinide, fesoterodine, fingolimod hydrochloride; Gabapentin enacarbil, gefitinib; hMaxi-K, human papillomavirus vaccine, HYAL-CT1101; Imatinib mesylate, indiplon, inolimomab, ISAtx-247; J591; Lacosamide, landiolol, lasofoxifene tartrate, lestaurtinib, lidocaine/prilocaine, linezolid, lixivaptan, lonafarnib, lopinavir, lopinavir/ritonavir, lumiracoxib; Natalizumab, nesiritide; OC-108, omalizumab, onercept, OSC; Palifermin, palonosetron hydrochloride, parathyroid hormone (human recombinant), parecoxib sodium, PD-MAGE-3 vaccine, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, pegsunercept, pelitinib, pitavastatin calcium, plerixafor hydrochloride, posaconazole, prasterone sulfate, pregabalin; Ramelteon, ranelic acid distrontium salt, rasburicase, rosuvastatin calcium, rotigotine, RSD-1235, rufinamide, rupatadine fumarate; Sarizotan hydrochloride, SHL-749, sirolimus-eluting stent, solifenacin succinate, sunitinib malate; Tadalafil, talampanel, tasidotin hydrochloride, Taxus, tegaserod maleate, telavancin hydrochloride, tenofovir disoproxil fumarate, tiotropium bromide, tocilizumab, tositumomab, treprostinil sodium, tridolgosir hydrochloride, TTS-CD3; Ularitide; Valdecoxib, Val-Tyr sardine peptidase, vardenafil hydrochloride hydrate, voriconazole; Yttrium (90Y) edotreotide, Yttrium 90 (90Y) ibritumomab tiuxetan; Zileuton, zucapsaicin.
2.The novel antidyskinetic drug sarizotan elicits different functional responses at human D2-like dopamine receptors.
Kuzhikandathil EV;Bartoszyk GD Neuropharmacology. 2006 Sep;51(4):873-84. Epub 2006 Jul 14.
Sarizotan (EMD 128130) is a chromane derivative that exhibits affinity at serotonin and dopamine receptors. Sarizotan effectively suppresses levodopa-induced dyskinesia in primate and rodent models of Parkinson's disease, and tardive dyskinesia in a rodent model. Results from clinical trials suggest that sarizotan significantly alleviates levodopa-induced dyskinesia. The functional effects of sarizotan on individual dopamine receptor subtypes are not known. Here we report the functional effects of sarizotan on human D2-like dopamine receptors (D2S, D2L, D3, D4.2 and D4.4) individually expressed in the AtT-20 neuroendocrine cell line. Using the coupling of D2-like dopamine receptors to G-protein coupled inward rectifier potassium channels we determined that sarizotan is a full agonist at D3 and D4.4 receptors (EC50=5.6 and 5.4 nM, respectively) but a partial agonist at D2S, D2L and D4.2 receptors (EC50=29, 23 and 4.5 nM, respectively). Consistent with its partial agonist property, sarizotan is an antagonist at D2S and D2L receptors (IC50=52 and 121 nM, respectively). Using the coupling of D2-like dopamine receptors to adenylyl cyclase we determined that sarizotan is a full agonist at D2L, D3, D4.
3.Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11C]WAY-100635 and [11C]raclopride.
Rabiner EA;Gunn RN;Wilkins MR;Sedman E;Grasby PM J Psychopharmacol. 2002 Sep;16(3):195-9.
The use of so-called, atypical antipsychotic medication is becoming more widespread in the treatment of psychotic disorders. EMD 128 130 is a novel compound acting as an agonist at the 5-HT1A receptor, and as an antagonist at the dopamine-2 (D2) receptor. This dual action may confer additional benefits over selective D2 antagonists in the treatment of psychotic disorders. In this study, we investigated the occupancy of EMD 128 130 in vivo at the human D2 and 5-HT1A receptors with positron emission tomography using the radiotracers [11C]raclopride and [11C]WAY-100635. Seven healthy volunteers were examined before and after 5 days of treatment with EMD 128 130, administered in an incremental dose building up to 50 mg, b.d. A significant occupancy was demonstrated at the human D2 receptor (40% following a dose of 50 mg, b.d.) while there was no consistent effect observed at the 5-HT1A receptor, despite a similar affinity of EMD 128 130 for cloned human D2 and 5-HT1A receptors, and the presence of typical, central 5-HT1A agonist side-effects. The differential effects of EMD 128 130 at the D2 and the 5-HT1A receptor (antagonist at D2 receptor, agonist at the 5-HTIA receptor) may explain the differences in occupancy observed.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related 5-HT Receptor Products

CAS 1217474-40-2 NAS-181

(CAS: 1217474-40-2)

NAS-181 is a 5-HT1B receptor antagonist with Ki value of 47 nM. It can increase synthesis and metabolism of 5-HT in the brain following systemic administration ...

Adrogolide Hydrochloride
(CAS: 166591-11-3)

The hydrochloride salt form of Adrogolide,a quinoline derivative, has been found to be a dopamine D1 receptor agonist that was once studied in Parkinson's disea...

CAS 1257326-22-9 NPEC-caged serotonin

NPEC-caged serotonin
(CAS: 1257326-22-9)

NPEC-caged serotonin is a caged version of serotonin.

CAS 65273-67-8 N,N-dibutyldopamine hydrobromide

N,N-dibutyldopamine hydrobromide
(CAS: 65273-67-8)

A dopamine receptor agonist.

CAS 138112-76-2 Agomelatine

(CAS: 138112-76-2)

Agomelatine is a melatoninergic agonist and selective antagonist of 5-HT2C receptors, and has been shown to be active in several animal models of depression. Ag...

CAS 250266-51-4 PNU 177864 hydrochloride

PNU 177864 hydrochloride
(CAS: 250266-51-4)

PNU 177864, a trifluromethoxy-phenylsulphonylamine, is a highly selective dopamine D3 receptor antagonist, which induces phospholipidosis and exhibits antischiz...

CAS 84225-95-6 Raclopride

(CAS: 84225-95-6)

Raclopride, also known as FLA 870, is a selective and potent dopamine D2/D3 receptor antagonist. It has high affinity (Kd = 1.2 nM) and high selectivity for D2 ...

CAS 115017-61-3 R(-)-Norapomorphine hydrobromide

R(-)-Norapomorphine hydrobromide
(CAS: 115017-61-3)

R(-)-Norapomorphine hydrobromide is a potent dopamine receptor agonist.

Quick Inquiry

Verification code

Featured Items